Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Commentary

The future sponsorship of CME in Canada: Industry, government, physicians or a blend?

Bernard Marlow
CMAJ July 20, 2004 171 (2) 150-151; DOI: https://doi.org/10.1503/cmaj.1040629
Bernard Marlow
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

A recent editorial in CMAJ1 pointed out that continuing medical education (CME) programs financed by pharmaceutical companies can present information in a biased manner — that, in effect, some of these are thinly disguised efforts to market products. The editorial questioned the roles of professional associations — including the College of Family Physicians of Canada — in providing oversight of CME content offered for educational credit. Certainly, there is evidence that the pharmaceutical industry can influence physician prescribing through marketing and educational efforts.2,3,4,5 In addition, many “unrestricted grants” from commercial sponsors focus on programs that cover an area of practice related to the donor's products, leaving many “orphan” topics that attract no financial support. Yet the fact remains that the pharmaceutical industry in Canada has been a major contributor to innovative, ethically conducted, continuing education programs and health education research. At the CACHE (Canadian Association of Continuing Health Education) meetings in 2002 and 2003, of 155 abstracts that passed a rigorous peer-review process and were accepted for presentation, 63 had authors or coauthors who worked for industry.

Because of the obvious bias that can result when a sponsor chooses the topics for CME and has a hand in writing content, proposals for tightening controls on programs sponsored by industry have been put forward. The US Accreditation Council on Continuing Medical Education — a national agency that accredits CME programs — has floated changes to its guidelines. Under the proposed changes, physicians who have accepted money from the pharmaceutical industry would be banned for life from presenting at accredited CME events. Although others have argued that there are advantages to this proposal,6 if it were put into effect it would empty lecterns and podia across the continent. Industry has recruited many of the best of our teachers and researchers for the development and delivery of their sponsored CME programs.

Sponsorship by industry has come under close scrutiny by government, medical organizations, the media and even industry itself. New proposals to regulate CME could soon become so restrictive as to choke off the financial support provided by industry to assist physicians in attending CME courses.7 The costs of CME are not trivial. Physicians must not only pay for the course and the costs of attending, but must continue to pay office overhead and lose income during their absences. Unlike other professionals, they cannot pass these costs on to their patients in the form of higher fees. If tougher restrictions on financing CME result in reductions (and perhaps even withdrawal) of commercial sponsorship, tuition fees for quality educational offerings will surely increase, adding to the burden on physicians who are trying to maintain their skills.

Some provinces have begun to pay physicians for attending CME programs. This is one solution. A second would be government grants to CME providers to create effective programs at no cost to physicians. A third would be to encourage and create new models whereby unrestricted grants from industry are truly unrestricted.

What are these new models? At the College of Family Physicians of Canada we have separated industry support from CME activities. For example, our Family Medicine Forum receives generous industry support. The CME program, however, is developed entirely by a planning committee with no pharmaceutical representation. Funding is derived from the sale of booths at an adjacent exhibit hall. Attendees have the option of just attending the lectures or of also visiting the companies' booths. Those attending the lectures receive CME credit. In essence, the organizers create a firewall between commercial interests and education, and the registrants benefit from reduced registration fees. There are many examples of pharmaceutical companies working with universities and professional societies to create quality educational programs free from commercial bias. We need to be more vigilant to prevent the few offenders from denigrating all.

The College of Family Physicians of Canada also has a role to play in approving CME courses for credit. Course organizers submit their programs to university CME offices or chapters of the College for review by assigned accreditors. They must submit all materials and answer a series of questions, which includes revealing their sources of commercial support. Once a program is accredited, there is currently no system to audit them as they are being presented. Over the past few months the College has been investigating a system of random audits, including assigned auditors, telephone interviews of attendees and standardized questions concerning commercial bias in post-course evaluations. The College anticipates that the new audit procedures will be implemented as soon as the evaluations are complete. The College of Family Physicians of Canada is in favour of blending these solutions: to pay physicians for lost income, to give government grants to universities and professional associations to create programs, and to continue to support and create cooperative models whereby providers and industry can educate physicians without bias.

𝛃 See related article page 149

Footnotes

  • Competing interests: None declared.

    Correspondence to: Dr. Bernard Marlow, College of Family Physicians of Canada, 2630 Skymark Ave., Mississauga ON L4W 5A4; 905 629-0893; bm{at}cfpc.ca

References

  1. 1.↵
    What's wrong with CME? [editorial]. CMAJ 2004;170(6):917.
    OpenUrlFREE Full Text
  2. 2.↵
    Wolfe SM. Why do American drug companies spend more than $12 billion a year pushing drugs? Is it education or promotion? J Gen Intern Med 1996;11:637-9.
    OpenUrlPubMed
  3. 3.↵
    Wazana A. Physicians and the pharmaceutical industry. Is a gift ever just a gift? JAMA 2000;283:373-80.
    OpenUrlCrossRefPubMed
  4. 4.↵
    Bowman MA. The impact of drug company funding on the content of continuing medical education. Mobius 1986;6:66-9.
    OpenUrl
  5. 5.↵
    Bowman MA, Pearle DL. Changes in drug prescribing patterns related to commercial company funding of continuing medical education. J Contin Educ Health Prof 1988;8:13-20.
    OpenUrlPubMed
  6. 6.↵
    Relman AS. Defending professional independence: ACCME's proposed new guidelines for commercial support of CME. JAMA 2003;289(18):2418-20.
    OpenUrlCrossRefPubMed
  7. 7.↵
    Van Harrison R. The uncertain future of continuing medical education: commercialism and shifts in funding. J Contin Educ Health Prof 2003;23(4):198-209.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 171 (2)
CMAJ
Vol. 171, Issue 2
20 Jul 2004
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The future sponsorship of CME in Canada: Industry, government, physicians or a blend?
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The future sponsorship of CME in Canada: Industry, government, physicians or a blend?
Bernard Marlow
CMAJ Jul 2004, 171 (2) 150-151; DOI: 10.1503/cmaj.1040629

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
The future sponsorship of CME in Canada: Industry, government, physicians or a blend?
Bernard Marlow
CMAJ Jul 2004, 171 (2) 150-151; DOI: 10.1503/cmaj.1040629
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Footnotes
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • Highlights of this issue
  • CME and the pharmaceutical industry: two worlds, three views, four steps
  • PubMed
  • Google Scholar

Cited By...

  • Industry involvement in continuing medical education: Time to say no
  • L'implication de l'industrie dans la formation medicale continue: Le temps est venu de dire non
  • Is continuing medical education a drug-promotion tool?: YES
  • La formation medicale continue est-elle un outil de promotion pharmaceutique?: OUI
  • Is continuing medical education a drug-promotion tool?: NO
  • La formation medicale continue est-elle un outil de promotion pharmaceutique?: NON
  • Does the C in CME stand for "Continuing" or "Commercial"?
  • Google Scholar

More in this TOC Section

  • Ensuring timely genetic diagnosis in adults
  • The case for improving the detection and treatment of obstructive sleep apnea following stroke
  • Laser devices for vaginal rejuvenation: effectiveness, regulation and marketing
Show more Commentary

Similar Articles

Collections

  • Topics
    • Medical careers

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire